Clearside Biomedical, Inc. (NASDAQ:CLSD) saw its stock decline 0.7% Thursday following the company’s announcement that it is exploring strategic alternatives to advance its proprietary Suprachoroidal ...

Fintel reports that on July 17, 2025, Needham downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from Buy to Hold. Analyst Price Forecast Suggests 571.05% Upside As of July 16, 2025, ...

Clay Thorp, a director at $CLSD, bought 15,000 shares of the company on 02-24-2025 for an estimated $13,800. This trade was reported by Quiver Quantitative using data from a recent SEC filing.

CLEARSIDE BIOMEDICAL ($CLSD) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.10 per share, missing estimates of -$0.10 by $0.00.

Review the current Clearside Biomedical Inc (CLSD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if CLSD is the best investment for you.

Clearside Biomedical (NASDAQ:CLSD) just reported results for the first quarter of 2024. Clearside Biomedical reported earnings per share of -17 cents. This was below the analyst estimate for EPS ...